So the fact you won't sell and invest elsewhere proves to me that you still believe your chances to increase your portfolio are better with ANIP then without ANIP.
Yet, when I suggest that we should be trading in the $15 to $20 range, even more if traded like the competition (if we come out with positive earnings in the $0.15 to $0.20), you suggest more likely $5 to $10.
Sorry, but you can't have it both ways.
They say no one listens to or acts on what we post on the message boards. But I have had conversations with both CEO's based on what was said on the boards. Obviously the chatter on the boards have some level of impact.
Intentionally or not, the negative sentiment you project is counter productive to everyone recovering their losses.
This is ANIP (pharmaceutical company) not BPAX (biotech company), it is time to acknowledge that and let it go. The future growth of generics in the US and the world will outpace branded pharmaceuticals. We are set up to benefit from the shift. But we also have the biotech pedigree in Biosantes portfolio of products that should allow us to take advantage of that as well without spending (diluting) any more to finance development.
Przybyl stated that he wanted to get us to small cap territory, where we will be more fairly traded especially since some funds cannot invest in micro cap stocks. That would put us in $30 PPS territory. I am figuring he would like to get us there before Teva gets approval and starts marketing Tesneo, to get a bigger bump from the news. Hopefully positive earnings gives him the ammo he needs.
In 2008, while at Akorn, Przybyl presented to the Oppenheimer conference just prior to posting Akorn's first positive earnings under his guidance. Oppenheimer who did the valuations for the merger has a conference in the second week of December. Don't be surprised if this is Pryzbyl's coming out party.
As for solving the case. You are right. But the game is far from over and I don't dictate the speed of the movements. I have solved cases that were over 7 years old. Sometimes you have to wait for a break (like when a wife leaves her husband and recant's the alibi). It takes patience and I am not going anywhere. Traders have little patience, investors do. In the meantime I patiently wait for the markets to turn onto ANIP for most likely the same reason you have not sold.
Market Data 
Markets 
AI
